Amanitin-Based Fc-Small Molecule-Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate...

Area of Science:

• Oncology
• Pharmacology
• Biotechnology

Background:

• Prostate cancer presents a significant global health challenge, particularly in advanced stages with limited therapeutic options.
• Targeted therapies, including antibody-drug conjugates (ADCs) and small-molecule drug conjugates (SMDCs), are emerging modalities for improving patient outcomes.
• Current SMDCs face limitations such as short plasma half-life and suboptimal efficacy, hindering clinical breakthroughs.

Purpose of the Study:

• To develop and evaluate a novel Fc-grafted small-molecule drug conjugate (Fc-SMDC) for prostate cancer treatment.
• To investigate the efficacy and safety of a first-in-class PSMA-targeted Fc-SMDC utilizing a non-cleavable linker.

Main Methods:

• Development of a novel Fc-SMDC by conjugating a cytotoxic payload (α-amanitin) to an Fc fragment via an engineered cysteine using a non-cleavable linker.
• Evaluation of the conjugate's plasma stability, tolerability in non-human primates, and anti-tumor efficacy in prostate cancer xenograft models.

Main Results:

• The novel Fc-SMDC demonstrated minimal premature drug release, increased plasma stability, and low systemic toxicity due to the non-cleavable linker.
• The conjugate exhibited high tolerability and an extended half-life, leading to prolonged tumor exposure and excellent anti-tumor efficacy in preclinical models.
• Favorable tolerability was observed in non-human primate studies.

Conclusions:

• The developed Fc-SMDC represents a first-in-class therapeutic approach for prostate cancer.
• The non-cleavable linker strategy enhances drug stability, reduces systemic toxicity, and improves anti-tumor efficacy.
• This novel Fc-SMDC holds significant potential as a next-generation treatment for advanced prostate cancer.